AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03047707 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: S-Shearwave and TE
Description: S-Shearwave elastography and Transient elastography (TE) are performed to evaluate hepatic stiffness.
Study NCT01728350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOPE - Helping Others through Purpose and Engagement
Study NCT00369824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Different formulations of GSK Biologicals' HPV vaccine (580299)
Description: Three doses of vaccine administered intramuscularly, with the second and third dose given one month and six months after the first dose respectively
Study NCT02537301 — intervention group
Intervention type: OTHER
Intervention: joining in the platform
Description: The activities (contents, chatting frequency etc.) of ERCP doctors on the chatting group were retrospectively extracted. The data related to the performance of ERCP (such as case volume, cannulation success rate and PEP etc.) by ERCP doctors were collected by a questionaire.
Study NCT04111588 — intervention group
Intervention type: OTHER
Intervention: Diagnostic Amino acid PET/MRI examination
Description: Diagnostic Amino acid PET/MRI examination
Study NCT00929617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental 1: exercise with 2 counseling types
Description: Patients will participate in 12 individual exercise sessions with an exercise specialist which will include stretching exercises and aerobic treadmill walking; plus attend 6 discussion group sessions with a trained facilitator; plus 3 face-to-face, individual counseling sessions with an exercise specialist
Study NCT01073280 — intervention group
Intervention type: PROCEDURE
Intervention: cerebral flexible endoscopy
Description: The investigators will make a burrhole in the precoronal suture introducing the flexible endoscope taking a cerebral and a basal meningeal biopsy
Study NCT04408859 — intervention group
Intervention type: DRUG
Intervention: Neoadjuvant Chemotherapy
Description: The patients receive neoadjuvant chemotherapy for 2-4 cycles before surgery.
Study NCT00929617 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care - written materials
Description: Patients will receive written materials about exercise for cancer survivors
Study NCT03058965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-958
Description: Subjects will undergo PET imaging using \[18F\]MNI-958, a PET radioligand for imaging tau.
Study NCT00997048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laying open
Description: Laying open Antibiotics Dalacin 300 mg tablets or iv infusion 600 mg
Study NCT00997048 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus excision
Description: Sinus excision Antibiotics Dalacin tablets 300 mg or iv infusion 600 mg
Study NCT03055403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M201-A Injection
Description: Active Substance: M201-A Route of administration: continuous intravenous injection
Study NCT03055403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline Placebo for M201-A Route of administration: continuous intravenous injection
Study NCT02330549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc 150 mg
Description: Cenicriviroc (CVC) 150 mg, administered orally once daily and taken every morning with food.
Study NCT02330549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching CVC administered orally once daily and taken every morning with food.
Study NCT02754830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3303560 - IV
Description: Administered IV
Study NCT02754830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution - IV
Description: Administered IV
Study NCT02754830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3303560 - SC
Description: Administered SC
Study NCT00813514 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VEGF genotyping
Description: blood sample for gene analysis
Study NCT00204997 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian transposition
Description: Laparoscopic ovarian transposition
Study NCT02073435 — intervention group
Intervention type: BEHAVIORAL
Intervention: Donor pain management
Description: The evidence-based donor pain management solution entails the following elements:~Preoperative Assessment and Management:~* Assessment of Patient Risk factors for Respiratory Depression (e.g. OSA Assessment: STOP BANG Questionnaire)~* Bowel preparation (e.g. Colace or Golytely)~* Patient Postoperative Pain Education - Educational handout on postoperative pain~At the end of the case in OR:~* Local Anesthetic (TAP block, OnQ device, intrathecal, local infiltration)~* I.V. Ketorolac (when adequate hemostasis is determined by surgeon and urine output is > 500cc)~* I.V. Steroids (Dexamethasone or Solumedrol)~Postoperative Management:~* NSAIDS x 72 hours followed by po cox-inhibitor until discharge (e.g. Celecoxib)~* Opioids (Dilaudid PCA followed by oral opioids (e.g., Tylenol #3))~Postoperative Assessment:~o CO2 monitoring in PACU/ICU for early monitoring of respiratory depression
Study NCT04415567 — intervention group
Intervention type: DRUG
Intervention: Lenvatinib
Description: The patients in lenvatinib group received oral lenvatinib (Eisai, Japan) 12 mg/day (for bodyweight (BW) ≥60 kg) or 8 mg/day (for BW \<60 kg) in 28-day cycles until HCC recurrence or serious adverse events (SAEs) or voluntary withdrawal. Dose interruptions followed by reductions for lenvatinib-related toxicities (to 8 mg and 4 mg/day, or 4 mg every other day) were permitted. All 14 patients took lenvatinib for more than 3 cycles.
Study NCT03338517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Helium Neon Laser
Study NCT04820543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of Botulinum type A
Description: The participates were allocated to two different application methods: Simplified Method for the first injection and Individualized Method 8 months later. All the patients underwent twice injection with each methods with no change of the BTX-A(Botox, Allergan, Irvine, CA) and other injection details: Lyophilized 100 U of Botox was reconstituted in 2.5 mL of 0.9% sodium chloride solution. The injections were made with a 27-gauge insulin syringe. The treatment was an outpatient procedure and all injections were performed by one of the authors (X.G.). No anesthesia was given during the procedure.
Study NCT02500238 — intervention group
Intervention type: OTHER
Intervention: Saliva sample
Description: All participants will provide a saliva sample.
Study NCT03058965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Florbetapir
Description: Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-958.
Study NCT03058965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DaTscan
Description: DaTscan SPECT imaging will be completed in those PSP subjects who have not previously had DATScan imaging as part of the screening procedures.
Study NCT02500238 — intervention group
Intervention type: OTHER
Intervention: Urine Sample
Description: All participants will provide a urine sample.
Study NCT02500238 — intervention group
Intervention type: OTHER
Intervention: Toe nail clippings
Description: All participants will provide toe nail clippings.
Study NCT04089865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic acid (TXA) is an antifibrinolytic medication used to reduce bleeding in a variety of medical settings. Patients will be randomized to receive either oral or intravenous tranexamic acid.
Study NCT04089865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid (TXA) is an antifibrinolytic medication used to reduce bleeding in a variety of medical settings. Patients will be randomized to receive either oral or intravenous tranexamic acid.
Study NCT02500238 — intervention group
Intervention type: OTHER
Intervention: Breath carbon monoxide test
Description: All participants will provide breath carbon monoxide tests
Study NCT05091294 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic injection rate in spinal anesthesia
Description: Administering intrathecal local anesthetics for all patients according to height and weight.
Study NCT02352792 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiochemotherapy with 70 Gy
Study NCT02352792 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy with 77 Gy
Study NCT02570763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS stimulation
Study NCT02570763 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS stimulation
Study NCT04596280 — intervention group
Intervention type: PROCEDURE
Intervention: Colonic Resection
Description: Resection of the colonic tract which has been interested by the acute diverticulitis
Study NCT03247543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered once daily
Study NCT03247543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 200mg SPN-812
Description: 200mg SPN-812 was administered once daily and compared to placebo
Study NCT03247543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400mg SPN-812
Description: 400mg SPN-812 was administered once daily and compared to placebo
Study NCT00491517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Patients will be given Sirolimus starting at the oral daily dose of 3 mg with periodically whole blood level measurements. The daily dose will be adjusted to keep sirolimus concentration within 10-15 ng/ml.
Study NCT00491517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: Antihypertensive drugs for patients with high blood pressure.
Study NCT00717626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS
Description: Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is \< 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.
Study NCT00145743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physio,pain,psychotherapy;social,nutrit.counselling&sports
Description: profile and treatment recommendations based on the profile vs. routine psychooncology
Study NCT03162978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT + POE
Description: Subjects will participate in high-intensity interval training (HIIT) with an additional treatment component to increase positive outcome expectations (POE) of exercise.
Study NCT03162978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT only
Description: Subjects will participate in high-intensity interval training (HIIT) only.
Study NCT00360451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent only Penn Resiliency Program (Adolescent PRP)
Description: In adolescent PRP, students learn both cognitive skills (recognizing the link between beliefs and emotions, challenging negative beliefs with evidence, making accurate attributions for events, and accurately assessing the ramifications of negative events) and behavioral problem-solving skills (decision making, assertiveness and negotiation, social skills, and relaxation).
Study NCT00360451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Penn Resiliency Program (Parent PRP)
Description: Parent PRP teaches parents to model and reinforce the skills taught in the adolescent program.
Study NCT01340079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual world
Description: health education using virtual world Second Life
Study NCT02133196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 (Arm 1) or 72,000 (Arm 2) IU/kg IV (based on total body weight) over 15 minutes every 8 hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to a maximum of 9 doses in Arm 1 and 12 doses in Arm 2.
Study NCT02133196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
Study NCT02133196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hour.
Study NCT02133196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Young TIL
Description: Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.
Study NCT01340079 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: face to face
Description: health education delivered in face to face groups
Study NCT01373060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral
Study NCT01373060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT04553991 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided QL block
Description: 20 mL of 0.25% bupivacaine was applied bilaterally at the anterolateral border of the QL at its junction with transversalis fascia
Study NCT04553991 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided TAP block
Description: 20 mL of 0.25% bupivacaine was applied bilaterally in the TAP
Study NCT02173652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356, high dose
Study NCT02173652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1356, low dose
Study NCT02946684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Adjuvant therapy to recFSH during ovarian stimulation
Study NCT02946684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Adjuvant therapy to recFSH during ovarian stimulation
Study NCT01741467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RT-CGM
Description: Dexcom Seven+
Study NCT03479931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Without placement of a catheter
Description: Elective cesarean section without preoperative placement of a urinary catheter.
Study NCT03479931 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: With placement of a catheter
Description: Elective cesarean section with preoperative placement of a urinary catheter.
Study NCT02948790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuristim
Description: Stimulation at high, medium and low intensity on apical, medial and basal Neuristim electrode
Study NCT02948790 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cochlear implant
Description: Stimulation at high, medium and low intensity on apical, medial and basal Cochlear implant electrode
Study NCT02450526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Study NCT02566707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: HIV therapy will be adapted: atazanavir 400mg QD
Study NCT02566707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: HIV therapy will be adapted: dolutegravir 50mg QD
Study NCT02566707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: HIV therapy will be adapted: lamivudine 300mg QD
Study NCT01112644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone naloxone prolonged release tablets (OXN PR)
Description: Different daily doses; intake every 12 hours
Study NCT01112644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone naloxone prolonged release tablets (OXN PR)
Description: Different daily doses; intake every 12 hours
Study NCT01112644 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PLA)
Description: Different daily doses; intake every 12 hours
Study NCT00011713 — intervention group
Intervention type: OTHER
Intervention: Completion questionnaires/providing biological samples
Description: Participant completes baseline interview at enrollment, then completes online questionnaire on lifestyle and medical history. Diet questionnaire is completed at home and mailed back. Online questionnaire about personal care product use and medications is completed at each scheduled study visit.
Study NCT03106194 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: case management
Study NCT00809458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Patients will take one 400 IU tablet of vitamin E or a placebo daily. Patients will continue on this treatment from the time of randomization to the day before surgery or the brachytherapy procedure. This is expected to be between 4 to 6 weeks. The patient will continue with his regular medications. The vitamin E will be supplied by the clinical trial through the UNM CRTC pharmacy.
Study NCT00809458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin E
Description: Patients will take one 400 IU tablet of vitamin E or a placebo daily. Patients will continue on this treatment from the time of randomization to the day before surgery or the brachytherapy procedure. This is expected to be between 4 to 6 weeks. The patient will continue with his regular medications. The vitamin E will be supplied by the clinical trial through the UNM CRTC pharmacy.
Study NCT00950079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: 3 mL/kg for 1 hour immediately before contrast injection , 1mg/kg/hr during procedure and 6 hours after procedure
Study NCT00950079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: 0.9% normal saline with 1 mL/kg/hr infusion 12 hours before procedure and 12 hours after procedure
Study NCT00084929 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Colonography
Description: CT colonography performed for comparison with colonoscopy results performed during the same screening assessment.
Study NCT04399512 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nonsurgical root canal treatment
Description: Nonsurgical root canal treatment will be given
Study NCT02068430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin 0.1%
Description: After topical anesthesia, 1 drop of Riboﬂavin 0.1% ophthalmic solution will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the 30 minute riboﬂavin pre-treatment period, the eye will be examined with blue light for the presence of a yellow ﬂare in the anterior chamber.
Study NCT02068430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UV-X™ Illumination System
Description: When the yellow ﬂare in the anterior chamber is conﬁrmed, the eye will be aligned under the UV-X™ light with the treatment plane at a working distance that is 50mm from the UV-X™ beam aperture. The correct aperture setting will be selected for the size of the eye (7.5 , 9.5, or 11 mm), and the eye will be irradiated for 30 minutes, during which time instillation of riboﬂavin will continue (1 drop every 2 minutes). At the end of 30 minutes, the UV light source will automatically switch to the off position. The operator will keep track of irradiation time independently to conﬁrm the actual treatment time.
Study NCT02953392 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anorganic Bovine Bone Graft Material
Description: Anorganic bovine bone graft material is intended for augmentation or reconstructive treatment of the alveolar ridge, filling periodontal defects, filling defects after root resection, apicoectomy, and cystectomy, filling extraction sockets to enhance preservation of the alveolar ridge, and elevation of maxillary sinus floor.
Study NCT02953392 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen Membrane
Description: Collagen dental wound dressing is intended for the management of oral wounds and sores, including; dental sores, oral ulcers, periodontal surgical wounds, suture sites, burns, extraction sites, surgical wounds, and traumatic wounds.
Study NCT02953392 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shelta Platform Switching Premium Implants
Description: Shelta implant systems are intended for immediate placement and function on single tooth and/or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
Study NCT01420393 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rhythm control
Description: Patients randomized to catheter ablation-based AF rhythm control group will receive optimal HF therapy and one or more aggressive catheter ablation, which include PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug
Study NCT01420393 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rate Control
Description: Patients in the rate control group will receive optimal HF therapy and rate control measures to achieve a resting HR \< 80 bpm and 6-minute walk HR \< 110 bpm.
Study NCT03999866 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: airtraq
Description: airtraq videolaryngoscope
Study NCT02953392 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shelta Platform Matching Premium Implants
Description: Shelta implant systems are intended for immediate placement and function on single tooth and /or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.